Xanthohumol microbiome and signature in adults with Crohn’s disease (the XMaS trial): a protocol for a phase II triple-masked, placebo-controlled clinical trial

Xanthohumol microbiome and signature in adults with Crohn’s disease (the XMaS trial): a protocol for a phase II triple-masked, placebo-controlled clinical trial

Abstract Background Xanthohumol (XN), a bioactive flavonoid from Humulus lupulus with anti-inflammatory properties, has potential benefits for patients with Crohn’s disease (CD), a type of inflammatory bowel disease. We recently completed and published results of a placebo-controlled phase I clinica...

Full description

Bibliographic Details
Main Authors: Blake O. Langley, Jennifer Joan Ryan, John Phipps, Lita Buttolph, Brenna Bray, Joseph E. Aslan, Thomas O. Metz, Jan F. Stevens, Ryan Bradley
Format: Article
Language:English
Published: BMC 2022-10-01
Series:Trials
Subjects:
Natural product
Xanthohumol
Crohn’s disease
Inflammatory bowel disease
Microbiome
Inflammation
Online Access:https://doi.org/10.1186/s13063-022-06782-z

Internet

https://doi.org/10.1186/s13063-022-06782-z

Similar Items